Related Experiment Video

Updated: May 25, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance

T E Taylor1, F B Furnari, W K Cavenee

  • 1Ludwig Institute for Cancer Research, La Jolla, CA, USA.

Current Cancer Drug Targets
|January 25, 2012
PubMed

Insights

Targeting the epidermal growth factor receptor (EGFR) in glioblastoma (GBM) shows promise but faces drug resistance. A multi-target approach is crucial for effective GBM treatment.

Area of Science:

  • Neuro-oncology
  • Molecular biology
  • Cancer genetics

Background:

  • Glioblastoma (GBM) is the most common malignant adult primary brain tumor.
  • EGFR gene amplification and mutation are characteristic genetic alterations in GBM.
  • Targeted therapies against EGFR and its mutant form (ΔEGFR) are under investigation for GBM treatment.

Purpose of the Study:

  • To review the current status of anti-EGFR agents for GBM.
  • To discuss the challenge of drug resistance to these targeted therapies.
  • To highlight the need for a multi-target approach in GBM treatment.

Main Methods:

  • Review of experimental and clinical data on anti-EGFR therapies for GBM.
  • Analysis of mechanisms underlying upfront and acquired drug resistance.
  • Discussion of future therapeutic strategies.

Main Results:

  • Experimental data for anti-EGFR agents in GBM are promising.
  • Clinical efficacy is significantly limited by drug resistance.
  • Resistance mechanisms necessitate alternative therapeutic strategies.

Conclusions:

  • Targeted therapies against EGFR are a key area of GBM research.
  • Overcoming drug resistance is essential for improving treatment outcomes.
  • A combination or multi-target strategy is likely required for future GBM therapies.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...